← Back to Search

Alpha-2 Adrenergic Agonist

Guanfacine for Hyperalgesia

Phase 4
Waitlist Available
Led By Jianren Mao, M.D., Ph.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Pivotal Trial
Drug Has Already Been Approved

Summary

This trial suggests that a dual medication approach of guanfacine and morphine may be a more effective treatment for chronic pain than either medication alone.

Eligible Conditions
  • Chronic Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Quantitative Sensory Testing (QST)
Secondary study objectives
Detecting Diffuse Noxious Inhibitory Control (DNIC)
Heat Pain Threshold
Heat Pain Tolerance
+2 more

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.

Trial Design

5Treatment groups
Active Control
Placebo Group
Group I: Morphine:Guanfacine 1mgActive Control2 Interventions
Group II: Placebo:Guanfacine 2mgActive Control2 Interventions
Group III: Morphine:PlaceboActive Control2 Interventions
Group IV: Morphine:Guanfacine 2mgActive Control2 Interventions
Group V: Placebo:PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
3,006 Previous Clinical Trials
13,307,082 Total Patients Enrolled
30 Trials studying Chronic Pain
4,813 Patients Enrolled for Chronic Pain
National Institutes of Health (NIH)NIH
2,810 Previous Clinical Trials
8,159,432 Total Patients Enrolled
26 Trials studying Chronic Pain
22,795 Patients Enrolled for Chronic Pain
National Institute on Drug Abuse (NIDA)NIH
2,579 Previous Clinical Trials
3,316,725 Total Patients Enrolled
64 Trials studying Chronic Pain
84,374 Patients Enrolled for Chronic Pain

Media Library

Guanfacine 2mg (Alpha-2 Adrenergic Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT01681264 — Phase 4
Chronic Pain Research Study Groups: Morphine:Guanfacine 1mg, Placebo:Guanfacine 2mg, Placebo:Placebo, Morphine:Placebo, Morphine:Guanfacine 2mg
Chronic Pain Clinical Trial 2023: Guanfacine 2mg Highlights & Side Effects. Trial Name: NCT01681264 — Phase 4
Guanfacine 2mg (Alpha-2 Adrenergic Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01681264 — Phase 4
Chronic Pain Patient Testimony for trial: Trial Name: NCT01681264 — Phase 4
~17 spots leftby Nov 2025